

TODAY'S MESSAGE

DOSING LIMITS FOR STELARA ENFORCED

EFFECTIVE AUG. 3, 2015!

Highmark Blue Cross Blue Shield Delaware (Highmark Delaware) is informing prescribers that weight-dosing limits for Stelara will be enforced on prior authorization requests effective Aug. 3, 2015, under the medical benefit. This requirement will apply to patients currently receiving Stelara and patients who are new to treatment with Stelara.

Per the FDA-approved label, Stelara dosing is as follows:

Psoriasis:

- For patients weighing ≤ 100 kilograms (220 pounds), the recommended dose is 45 mg initially and four weeks later, followed by 45 mg every 12 weeks.
- For patients weighing > 100 kilograms (220 pounds), the recommended dose is 90 mg initially and four weeks later, followed by 90 mg every 12 weeks.

Psoriatic Arthritis:

- The recommended dose is 45 mg initially and four weeks later, followed by 45 mg every 12 weeks.
- For patients with co-existent moderate-to-severe plaque psoriasis weighing > 100 kilograms (220 pounds), the recommended dose is 90 mg initially and four weeks later, followed by 90 mg every 12 weeks.

To avoid disruption of patient therapy, please contact your patient, if necessary, to issue a revised order within the quantity/dosage limit noted above.

Use NaviNet[®] for any medical injectable drug authorization requests. NaviNet not only saves time, but also can notify you if a duplicate request has already been received by Highmark Delaware and clarifies if the patient is a Highmark Delaware member with active medical benefits.

We appreciate your attention to this important feature that helps ensure safe and appropriate medication usage for your patients, our members.